
Kepler Cheuvreux downgraded bioMerieux (BMXMF) to Hold from Buy with a EUR 95 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| BMXMF | bioMerieux | 102.14 | -21.51 | -17.39% |
| Name | Price | % Change | |
|---|---|---|---|
| $102.14 | -17.39% |

Kepler Cheuvreux downgraded bioMerieux (BMXMF) to Hold from Buy with a EUR 95 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

JPMorgan raised the firm’s price target on bioMerieux (BMXMF) to EUR 84 from EUR 71.60 and keeps a Neutral rating on the shares. Published first on TheFly – the ultimate

Deutsche Bank analyst Jan Koch upgraded bioMerieux (BMXMF) to Buy from Hold with a price target of EUR 103, up from EUR 75. The firm no longer sees downside risk

Morgan Stanley raised the firm’s price target on bioMerieux (BMXMF) to EUR 66 from EUR 64 and keeps an Underweight rating on the shares. Published first on TheFly – the

Deutsche Bank lowered the firm’s price target on bioMerieux (BMXMF) to EUR 75 from EUR 78 and keeps a Hold rating on the shares. Published first on TheFly – the

Morgan Stanley downgraded bioMerieux (BMXMF) to Underweight from Equal Weight with a price target of EUR 64, down from EUR 100. The firm sees a slowdown in respiratory volumes impacting

Deutsche Bank analyst Jan Koch lowered the firm’s price target on bioMerieux (BMXMF) to EUR 78 from EUR 81 and keeps a Hold rating on the shares. Published first on

Piper Sandler initiated coverage of bioMerieux (BMXMF) with a Neutral rating and EUR 80 price target The firm launched coverage of the life science tools sector with a “feet in

UBS downgraded bioMerieux (BMXMF) to Neutral from Buy with a price target of EUR 80, down from EUR 138. The company’s near-term visibility is less than previously assumed, the analyst

JPMorgan lowered the firm’s price target on bioMerieux (BMXMF) to EUR 71.60 from EUR 120.50 and keeps a Neutral rating on the shares. Published first on TheFly – the ultimate
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| hold | Downgraded | Nov 5, 2026 | ||||
| hold | Reiterated | Nov 4, 2026 | ||||
| hold | Reiterated | Nov 4, 2026 | ||||
| hold | Reiterated | Nov 3, 2026 | ||||
| buy | Upgraded | Oct 28, 2026 | ||||
| hold | Reiterated | Oct 23, 2026 | ||||
| sell | Reiterated | Sep 11, 2026 | ||||
| hold | Reiterated | Jul 29, 2026 | ||||
| hold | Downgraded | Jan 28, 2026 | ||||
| hold | Upgraded | Dec 12, 2025 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 26, 2027Before Open | $11.77B | $2.81 | $1.31B | -4.00 | 23.07 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.